These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

468 related articles for article (PubMed ID: 24496668)

  • 1. Impact of the introduction of rituximab in first-line follicular lymphoma: a retrospective study of 247 unselected patients referred to a single institution with a long-term follow-up.
    Nicolas-Virelizier E; Ségura-Ferlay C; Ghesquières H; Chassagne-Clément C; Gargi T; Biron P; Belhabri A; Rey P; Faurie P; Chabaud S; Sebban C
    Hematol Oncol; 2015 Mar; 33(1):1-8. PubMed ID: 24496668
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcomes of Treatment in Slovene Follicular Lymphoma Patients.
    Južnič Šetina T; Borštnar S; Jezeršek Novaković B
    Clin Lymphoma Myeloma Leuk; 2015 Oct; 15(10):586-91. PubMed ID: 26423702
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial.
    Coiffier B; Osmanov EA; Hong X; Scheliga A; Mayer J; Offner F; Rule S; Teixeira A; Walewski J; de Vos S; Crump M; Shpilberg O; Esseltine DL; Zhu E; Enny C; Theocharous P; van de Velde H; Elsayed YA; Zinzani PL;
    Lancet Oncol; 2011 Aug; 12(8):773-84. PubMed ID: 21724462
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Frontline bortezomib and rituximab for the treatment of newly diagnosed high tumour burden indolent non-Hodgkin lymphoma: a multicentre phase II study.
    Evens AM; Smith MR; Lossos IS; Helenowski I; Millenson M; Winter JN; Rosen ST; Gordon LI
    Br J Haematol; 2014 Aug; 166(4):514-20. PubMed ID: 24761968
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Autologous and allogeneic stem-cell transplantation for transformed follicular lymphoma: a report of the Canadian blood and marrow transplant group.
    Villa D; Crump M; Panzarella T; Savage KJ; Toze CL; Stewart DA; MacDonald DA; Buckstein R; Lee C; Alzahrani M; Rubinger M; Foley R; Xenocostas A; Sabloff M; Muccilli A; Chua N; Couture F; Larouche JF; Cohen S; Connors JM; Ambler K; Al-Tourah A; Ramadan KM; Kuruvilla J
    J Clin Oncol; 2013 Mar; 31(9):1164-71. PubMed ID: 23401459
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peripheral blood involvement in patients with follicular lymphoma: a rare disease manifestation associated with poor prognosis.
    Sarkozy C; Baseggio L; Feugier P; Callet-Bauchu E; Karlin L; Seymour JF; Lebras L; Michallet AS; Offner F; Dumas O; Traverse-Glehen A; Ffrench M; Lopez-Guillermo A; Berger F; Coiffier B; Felman P; Salles G
    Br J Haematol; 2014 Mar; 164(5):659-67. PubMed ID: 24274024
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Durable event-free survival following autologous stem cell transplant for relapsed or refractory follicular lymphoma: positive impact of recent rituximab exposure and low-risk Follicular Lymphoma International Prognostic Index score.
    Peters AC; Duan Q; Russell JA; Duggan P; Owen C; Stewart DA
    Leuk Lymphoma; 2011 Nov; 52(11):2124-9. PubMed ID: 21740097
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of nodular lymphocyte predominant Hodgkin lymphoma in the modern era.
    King MT; Donaldson SS; Link MP; Natkunam Y; Advani RH; Hoppe RT
    Int J Radiat Oncol Biol Phys; 2015 May; 92(1):67-75. PubMed ID: 25863755
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fludarabine-mitoxantrone-rituximab regimen in untreated intermediate/high-risk follicular non-Hodgkin's lymphoma: experience on 142 patients.
    Zinzani PL; Pellegrini C; Broccoli A; Casadei B; Argnani L; Pileri S
    Am J Hematol; 2013 Nov; 88(11):E273-6. PubMed ID: 23843267
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rituximab with or without bevacizumab for the treatment of patients with relapsed follicular lymphoma.
    Hainsworth JD; Greco FA; Raefsky EL; Thompson DS; Lunin S; Reeves J; White L; Quinn R; DeBusk LM; Flinn IW
    Clin Lymphoma Myeloma Leuk; 2014 Aug; 14(4):277-83. PubMed ID: 24679633
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bortezomib plus rituximab versus rituximab in patients with high-risk, relapsed, rituximab-naïve or rituximab-sensitive follicular lymphoma: subgroup analysis of a randomized phase 3 trial.
    Zinzani PL; Khuageva NK; Wang H; Garicochea B; Walewski J; Van Hoof A; Soubeyran P; Caballero D; Buckstein R; Esseltine DL; Theocharous P; Enny C; Zhu E; Elsayed YA; Coiffier B
    J Hematol Oncol; 2012 Oct; 5():67. PubMed ID: 23088650
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rituximab purging and/or maintenance in patients undergoing autologous transplantation for relapsed follicular lymphoma: a prospective randomized trial from the lymphoma working party of the European group for blood and marrow transplantation.
    Pettengell R; Schmitz N; Gisselbrecht C; Smith G; Patton WN; Metzner B; Caballero D; Tilly H; Walewski JA; Bence-Bruckler I; To B; Geisler CH; Schots R; Kimby E; Taverna CJ; Kozák T; Dreger P; Uddin R; Ruiz de Elvira C; Goldstone AH
    J Clin Oncol; 2013 May; 31(13):1624-30. PubMed ID: 23547078
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Addition of Rituximab to Involved-Field Radiation Therapy Prolongs Progression-free Survival in Stage I-II Follicular Lymphoma: Results of a Multicenter Study.
    Ruella M; Filippi AR; Bruna R; Di Russo A; Magni M; Caracciolo D; Passera R; Matteucci P; Di Nicola M; Corradini P; Parvis G; Gini G; Olivieri A; Ladetto M; Ricardi U; Tarella C; Devizzi L
    Int J Radiat Oncol Biol Phys; 2016 Mar; 94(4):783-91. PubMed ID: 26972651
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic significance of programmed cell death-1-positive cells in follicular lymphoma patients may alter in the rituximab era.
    Takahashi H; Tomita N; Sakata S; Tsuyama N; Hashimoto C; Ohshima R; Matsuura S; Ogawa K; Yamamoto W; Kameda Y; Enaka M; Inayama Y; Kasahara M; Takekawa Y; Onoda N; Motomura S; Ishigatsubo Y; Takeuchi K
    Eur J Haematol; 2013 Apr; 90(4):286-90. PubMed ID: 23331211
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rituximab maintenance therapy until progression after rituximab and chemotherapy induction in patients with follicular lymphoma.
    Yared J; Kimball A; Baer MR; Bahrain H; Auerbach M
    Clin Lymphoma Myeloma Leuk; 2013 Jun; 13(3):253-7. PubMed ID: 23352637
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Autologous hematopoietic stem cell transplantation for relapsed follicular lymphoma: safety profile and clinical outcome in a single-center experience.
    Helbig G; Krawczyk-Kulis M; Kopinska A; Liwoch R; Kyrcz-Krzemien S
    Med Oncol; 2014 Dec; 31(12):310. PubMed ID: 25373321
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fludarabine plus mitoxantrone with and without rituximab versus CHOP with and without rituximab as front-line treatment for patients with follicular lymphoma.
    Zinzani PL; Pulsoni A; Perrotti A; Soverini S; Zaja F; De Renzo A; Storti S; Lauta VM; Guardigni L; Gentilini P; Tucci A; Molinari AL; Gobbi M; Falini B; Fattori PP; Ciccone F; Alinari L; Martelli M; Pileri S; Tura S; Baccarani M
    J Clin Oncol; 2004 Jul; 22(13):2654-61. PubMed ID: 15159414
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fludarabine, cyclophosphamide and rituximab as first-line treatment in patients with newly diagnosed follicular lymphoma.
    De la Cruz Vicente F; Carrillo-Cruz E; Rodriguez MS; Marín Niebla A; Galiana ML; Gonzalez JF; Cuadrado IM; Campos JG; Tocino IE; Rios-Herranz E; Perez-Simón JA
    Eur J Haematol; 2014 Dec; 93(6):469-75. PubMed ID: 24853381
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Yttrium 90-ibritumomab tiuxetan plus rituximab maintenance as initial therapy for patients with high-tumor-burden follicular lymphoma: a Wisconsin Oncology Network study.
    Rajguru S; Kristinsdottir T; Eickhoff J; Peterson C; Meyer CM; Traynor AM; Kahl BS
    Clin Adv Hematol Oncol; 2014 Aug; 12(8):509-15. PubMed ID: 25356575
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prespecified candidate biomarkers identify follicular lymphoma patients who achieved longer progression-free survival with bortezomib-rituximab versus rituximab.
    Coiffier B; Li W; Henitz ED; Karkera JD; Favis R; Gaffney D; Shapiro A; Theocharous P; Elsayed YA; van de Velde H; Schaffer ME; Osmanov EA; Hong X; Scheliga A; Mayer J; Offner F; Rule S; Teixeira A; Romejko-Jarosinska J; de Vos S; Crump M; Shpilberg O; Zinzani PL; Cakana A; Esseltine DL; Mulligan G; Ricci D
    Clin Cancer Res; 2013 May; 19(9):2551-61. PubMed ID: 23549871
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.